Company intelligence / Profile preview
Cryo-Cell International
Oldsmar, Florida, United Statescryo-cell.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Cryo-Cell has released over 100 cord blood collections for transplants and dozens for autologous therapy, with ongoing and anticipated clinical studies in neurological disorders and regenerative medicine. Early results through collaborations (notably Duke University) indicate potential benefit for indications such as autism and cerebral palsy, with access to treatment via expanded access programs under FDA-approved INDs.[1]
- Therapeutic areas
- EndocrinologyRheumatologyInfectious DiseasesNeurologyHematologyPsychiatryOncology
- Modalities
- Stem cell therapyCell therapyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Duke University (exclusive cellular therapy license and clinical partnership)Saneron CCEL TherapeuticsStanford University
Beyond the preview
Go deeper on Cryo-Cell International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cryo-Cell International.